According to the research report titled ‘Global Neuralgia Treatment Market Size study, by Treatment (Drug Based, Surgery), by End-User (Hospitals & Clinics, Ambulatory Surgery Center, Others) and Regional Forecasts 2020-2027’, available with Market Study Report, global neuralgia treatment market was assessed at USD 1.8 billion in 2019 and is projected to reach USD 2.9 billion by the year 2027, growing at a yearly rate of 6% throughout.
 

Growing occurrence of diabetes and trigeminal neuralgia, in consort with rising geriatric population are propelling the growth of global neuralgia treatment market. According to IDF Diabetes Atlas in 2019, 68 million people in Europe are speculated to have diabetes by the year 2045, and the related healthcare expenditure to reach USD 214 billion.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2956044/
 

International Diabetic Federation further reports that, as of 2019, 463 million adults aged between 20-79 years had diabetes worldwide and this number is reckoned to reach 700 million by 2045.
 

For the unversed, neuralgia is an aberrant symptom causing severe pain owing to a damaged or irritated nerve. Neuralgia treatment methods effectively cure disorders like diabetes and heart diseases resulting from this nerve damage.
 

Availability of better options for diagnostic criteria, and increasing access to specialized treatment are stimulating global neuralgia treatment market outlook. Moreover, adoption of various types of treatment like physical therapy, medicines to regulate blood sugar of diabetic patients, surgery to reduce pressure, and epidural injections to decrease pain are also adding to industry remuneration.
 

On the other hand, shortage of skilled healthcare professionals, and high cost of treatment impedes growth of global neuralgia treatment market.
 

Based on types of treatment, the industry is divided into drug based, and surgery. According to end user spectrum, the market is bifurcated into ambulatory surgery centers, and hospitals & clinics among others.
 

Regionally speaking, North America captured majority of global neuralgia treatment market share in the past year, due to presence of many vendors in the region, and increasing awareness about neuralgia treatment among people.
 

Meanwhile, Asia Pacific market is projected to showcase lucrative growth trends over the forecast period, owing to rising geriatric population in India and China, and increasing prevalence of diabetes and neuralgic disorders.
 

Key players influencing global neuralgia treatment industry trends are Abbott Laboratories, Cadila Healthcare Limited, Allergan Inc., Trigemina Inc., GlaxoSmithKline plc, Biogen Inc., Merz Pharma GmbH & Co. KGaA, Pfizer Inc., H. Lundbeck A/S, and Novartis International AG.